Company Cumberland Pharmaceuticals Inc.

Equities

CPIX

US2307701092

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.68 USD -6.15% Intraday chart for Cumberland Pharmaceuticals Inc. -7.18% -6.23%

Business Summary

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a prescription laxative, for the treatment of constipation, and Omeclamox-Pak, oral, for the treatment of Helicobacter pylori infection and related duodenal ulcer disease. Its brands also include Sancuso transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, and Vibativ injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.

Number of employees: 91

Sales per Business

USD in Million2022Weight2023Weight Delta
Specialty Pharmaceutical Products
100.0 %
42 100.0 % 40 100.0 % -5.85%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
97.2 %
41 96.4 % 38 97.2 % -5.08%
Non-United States
2.8 %
2 3.6 % 1 2.8 % -26.67%

Managers

Managers TitleAgeSince
Chief Executive Officer 65 99-01-06
Director of Finance/CFO 67 18-12-31
Compliance Officer 67 02-12-31
Director/Board Member 72 99-01-05
Investor Relations Contact - -
Sales & Marketing 58 17-12-31
Sales & Marketing - 10-12-31
Corporate Officer/Principal 44 16-12-31
Sales & Marketing - 08-12-31
Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 59 22-07-14
Chief Executive Officer 65 99-01-06
Director/Board Member 66 17-01-17
Director/Board Member 74 18-09-18
Director/Board Member 72 99-01-05
Director/Board Member 76 09-12-31
Director/Board Member 49 16-06-09

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 14,176,529 7,776,179 ( 54.85 %) 0 54.85 %

Shareholders

NameEquities%Valuation
A. Kazimi
38.21 %
5,695,557 38.21 % 12 M $
Renaissance Technologies LLC
3.689 %
549,863 3.689 % 1 M $
Vanguard Group, Inc. (Subfiler)
2.511 %
374,251 2.511 % 797 155 $
Dimensional Fund Advisors LP
2.455 %
365,934 2.455 % 779 439 $
Bridgeway Capital Management LLC
1.923 %
286,655 1.923 % 610 575 $
241,277 1.619 % 513 920 $
Acadian Asset Management LLC
1.262 %
188,164 1.262 % 400 789 $
BlackRock Institutional Trust Co. NA
0.7447 %
110,990 0.7447 % 236 409 $
Jacobs Joey Anthony /Estate Of/
0.6603 %
98,415 0.6603 % 209 624 $
Geode Capital Management LLC
0.5721 %
85,274 0.5721 % 181 634 $

Company contact information

Cumberland Pharmaceuticals, Inc.

1600 West End Avenue Suite 1300

37203, Nashville

+

http://www.cumberlandpharma.com
address Cumberland Pharmaceuticals Inc.(CPIX)